BioSpace News Archive

AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today the initiation of clinical trials for ImmunoPass, the Company’s rapid point-of-care test that semi-quantitatively measures levels of neutralizing antibodies to COVID-19. As a variety of COVID-19 vaccines begin rolling out to the general public, immunity

Chengdu Kanghong Pharmaceutical Group, has received Special Protocol Assessments from the Food and Drug Administration for three new indications for its biologic drug conbercept.

Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, today announced that the European Medicines Agency (EMA) granted Priority Medicines (PRIME) designation to ARU-1801, a one-time investigational gene therapy for sickle cell disease (SCD)

Tetra Tech, Inc. (NASDAQ: TTEK), a high-end consulting and engineering firm, announced today that it has further expanded its advanced analytics business with the addition of Coanda Research & Development Corporation, based in Burnaby, British Columbia.

Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today that it has been granted approval by the Bellberry Human Research Ethics Committee (HREC) in Australia to add a multiple dose cohort to its Phase 1 clinical st

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced U.S. Food and Drug Administration (FDA) clearance of the CellFX® System for dermatologic procedures requiring ablation and resurfacing of the skin.

LifeNet Health LifeSciences has successfully isolated three types of primary human lung epithelial cells from a single donor.

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicines, announced today that it has obtained interim results for its ongoing in-vivo study evaluating the efficacy of the company’s proprietary drug candidate RCC-33 for colorectal cance

The Lupus Foundation of America announced the recipients of its most prestigious annual awards, recognizing three leading lupus scientists.

Scipher Medicine, a precision immunology company matching patients with the most effective therapy, announced today they have partnered with Massachusetts Institute of Technology Center for Biomedical Innovation’s New Drug Development Paradigms Initiative (NEWDIGS) in their mission to enhance the capacity of the global biomedical innovation system to reliably and sustainably deliver new, better, and affordable therapeutics to patients faster.